Table 4 Top ranked canonical pathways from IPA after performing basic core analysis.
From: Longitudinal genome-wide DNA methylation changes in response to kidney failure replacement therapy
Canonical pathway title | p-value | |
|---|---|---|
Controls vs dialysis patients baseline | Protein ubiquitination pathway | 3.8 × 10–10 |
Cell cycle: G1/S checkpoint regulation | 2 × 10–6 | |
Role of BRCA1 in DNA damage response | 1.1 × 10–5 | |
Cell cycle control of chromosomal replication | 1.3 × 10–5 | |
Cell cycle: G2/M DNA damage checkpoint regulation | 4.1 × 10–5 | |
RAR activation | 8.1 × 10–5 | |
Controls vs KTx patients baseline | Molecular mechanisms of cancer | 1.3 × 10–13 |
Axonal guidance signalling | 3.1 × 10–10 | |
Integrin signalling | 6.9 × 10–9 | |
Fcγ receptor-mediated phagocytosis in macrophages and monocytes | 1.5 × 10–8 | |
Protein kinase A signalling | 1.7 × 10–8 | |
G-protein coupled receptor signalling | 3 × 10–8 | |
Controls vs dialysis patients 12 months | Cyclins and cell cycle regulation | 1.6 × 10–7 |
Cell cycle: G1/S checkpoint regulation | 3.5 × 10–7 | |
Small cell lung cancer signalling | 2.9 × 10–6 | |
Prostate cancer signalling | 2 × 10–5 | |
Chronic myeloid leukemia signalling | 5.5 × 10–5 | |
Molecular mechanisms of cancer | 1.3 × 10–4 | |
Controls vs KTx patients 12 months | Integrin signalling | 9.3 × 10–9 |
Molecular mechanisms of cancer | 1 × 10–8 | |
Paxillin signalling | 1.4 × 10–7 | |
Tec kinase signalling | 6.5 × 10–7 | |
T cell receptor signalling | 9.4 × 10–7 | |
Role of NFAT in regulation of the immune response | 1.1 × 10–6 | |
Controls vs alla | IGF-1 signalling | 3.3 × 10–5 |
Rac signalling | 5.5 × 10–5 | |
STAT3 pathway | 1.3 × 10–4 | |
Breast cancer regulation by Stathmin1 | 1.7 × 10–4 | |
PTEN signalling | 1.7 × 10–4 |
